Enhancing clinical trial sites in low- and middle-income countries to facilitate product development in response to the COVID-19 pandemic
The swift development of coronavirus disease 2019 (COVID-19) vaccines marked a monumental effort in global coordination and collaboration; however, there remained major disparities in vaccine access and research capacity across countries. Unequal participation in vaccine development studies from low...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
15 June 2025
|
| In: |
Clinical infectious diseases
Year: 2025, Jahrgang: 80, Pages: S1-S8 |
| ISSN: | 1537-6591 |
| DOI: | 10.1093/cid/ciaf094 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1093/cid/ciaf094 Verlag, kostenfrei, Volltext: https://academic.oup.com/cid/article/80/Supplement_1/S1/8210485 
|
| Verfasserangaben: | Sophie S.Y. Kang, Birkneh Tilahun Tadesse, Hyon Jin Jeon, Mosoka P. Fallah, Nebiyu Dereje, Olayinka Stephen Ilesanmi, Solomon Mequanente Abay, Betelhem I. Tekle, Hayoung G. Son, Laxman Shrestha, Anita Shrestha, Hasia V. Ramiso, Vincent Canouet, Yeonseon Kim, Kwaku Poku Asante, Japhet Anim, Seyram Kaali, Maria Rosario Capeding, Ilesh V. Jani, Igor Capitine, Arlete Mahumane, T. Anh Wartel, Andrea Haekyung Haselbeck, Tarun Saluja, and Florian Marks |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1946279323 | ||
| 003 | DE-627 | ||
| 005 | 20251217091748.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251217s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciaf094 |2 doi | |
| 035 | |a (DE-627)1946279323 | ||
| 035 | |a (DE-599)KXP1946279323 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kang, Sophie |e VerfasserIn |0 (DE-588)136410637X |0 (DE-627)1923961683 |4 aut | |
| 245 | 1 | 0 | |a Enhancing clinical trial sites in low- and middle-income countries to facilitate product development in response to the COVID-19 pandemic |c Sophie S.Y. Kang, Birkneh Tilahun Tadesse, Hyon Jin Jeon, Mosoka P. Fallah, Nebiyu Dereje, Olayinka Stephen Ilesanmi, Solomon Mequanente Abay, Betelhem I. Tekle, Hayoung G. Son, Laxman Shrestha, Anita Shrestha, Hasia V. Ramiso, Vincent Canouet, Yeonseon Kim, Kwaku Poku Asante, Japhet Anim, Seyram Kaali, Maria Rosario Capeding, Ilesh V. Jani, Igor Capitine, Arlete Mahumane, T. Anh Wartel, Andrea Haekyung Haselbeck, Tarun Saluja, and Florian Marks |
| 264 | 1 | |c 15 June 2025 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 22. Juli 2025 | ||
| 500 | |a Gesehen am 17.12.2025 | ||
| 520 | |a The swift development of coronavirus disease 2019 (COVID-19) vaccines marked a monumental effort in global coordination and collaboration; however, there remained major disparities in vaccine access and research capacity across countries. Unequal participation in vaccine development studies from low- and middle- income countries (LMICs) clearly signaled an urgent need to strengthen health research infrastructure in those regions.With funding from the Gates Foundation (GF), this site readiness initiative carried out rapid capacity enhancement activities to enable large-scale, Phase 3 pivotal clinical trial conduct in LMICs. The International Vaccine Institute (IVI) worked with site partners in four countries (Mozambique, Ghana, Nepal, and the Philippines) after conducting feasibility assessments for site selection. Site-specific gaps were identified, and capacity building activities focused on staff training, site infrastructure, and resource mobilization were carried out over roughly 7 months from October 2020 to May 2021.Despite pandemic-related challenges such as supply chain shortages, by the end of the capacity building efforts all sites were either contracted to or in discussions with trial sponsors to conduct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine studies. This article provides an overview of the site selection process, critical components of site establishment, and final site readiness evaluations carried out amidst a global health emergency.This experience illustrates the value of research capacity enhancement as essential to both pandemic preparedness and global health equity. The lessons learned are being carried into an ongoing initiative across West Africa, currently underway as the “Advancing Research Capabilities in West Africa (ARC-WA).” | ||
| 700 | 1 | |a Tadesse, Birkneh Tilahun |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jeon, Hyon Jin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fallah, Mosoka P |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dereje, Nebiyu |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ilesanmi, Olayinka Stephen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Abay, Solomon Mequanente |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tekle, Betelhem I |e VerfasserIn |4 aut | |
| 700 | 1 | |a Son, Hayoung G |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shrestha, Laxman |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shrestha, Anita |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ramiso, Hasia V |e VerfasserIn |4 aut | |
| 700 | 1 | |a Canouet, Vincent |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kim, Yeonseon |e VerfasserIn |4 aut | |
| 700 | 1 | |a Asante, Kwaku Poku |e VerfasserIn |4 aut | |
| 700 | 1 | |a Anim, Japhet |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kaali, Seyram |e VerfasserIn |4 aut | |
| 700 | 1 | |a Capeding, Maria Rosario |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jani, Ilesh V |e VerfasserIn |4 aut | |
| 700 | 1 | |a Capitine, Igor |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mahumane, Arlete |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wartel, T Anh |e VerfasserIn |4 aut | |
| 700 | 1 | |a Haselbeck, Andrea Haekyung |e VerfasserIn |4 aut | |
| 700 | 1 | |a Saluja, Tarun |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marks, Florian |d 1975- |e VerfasserIn |0 (DE-588)130584258 |0 (DE-627)504163736 |0 (DE-576)298281589 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases |d Oxford : Oxford Journals, 1992 |g 80(2025), Supplement_1, S1-S8 |h Online-Ressource |w (DE-627)320418308 |w (DE-600)2002229-3 |w (DE-576)090881834 |x 1537-6591 |7 nnas |a Enhancing clinical trial sites in low- and middle-income countries to facilitate product development in response to the COVID-19 pandemic |
| 773 | 1 | 8 | |g volume:80 |g year:2025 |g supplement:Supplement_1 |g pages:S1-S8 |g extent:8 |a Enhancing clinical trial sites in low- and middle-income countries to facilitate product development in response to the COVID-19 pandemic |
| 856 | 4 | 0 | |u https://doi.org/10.1093/cid/ciaf094 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://academic.oup.com/cid/article/80/Supplement_1/S1/8210485 |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20251217 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 130584258 |a Marks, Florian |m 130584258:Marks, Florian |d 910000 |d 912800 |e 910000PM130584258 |e 912800PM130584258 |k 0/910000/ |k 1/910000/912800/ |p 25 |y j | ||
| 999 | |a KXP-PPN1946279323 |e 4829538856 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1946279323","language":["eng"],"note":["Online verfügbar: 22. Juli 2025","Gesehen am 17.12.2025"],"origin":[{"dateIssuedDisp":"15 June 2025","dateIssuedKey":"2025"}],"name":{"displayForm":["Sophie S.Y. Kang, Birkneh Tilahun Tadesse, Hyon Jin Jeon, Mosoka P. Fallah, Nebiyu Dereje, Olayinka Stephen Ilesanmi, Solomon Mequanente Abay, Betelhem I. Tekle, Hayoung G. Son, Laxman Shrestha, Anita Shrestha, Hasia V. Ramiso, Vincent Canouet, Yeonseon Kim, Kwaku Poku Asante, Japhet Anim, Seyram Kaali, Maria Rosario Capeding, Ilesh V. Jani, Igor Capitine, Arlete Mahumane, T. Anh Wartel, Andrea Haekyung Haselbeck, Tarun Saluja, and Florian Marks"]},"id":{"eki":["1946279323"],"doi":["10.1093/cid/ciaf094"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Enhancing clinical trial sites in low- and middle-income countries to facilitate product development in response to the COVID-19 pandemic","title_sort":"Enhancing clinical trial sites in low- and middle-income countries to facilitate product development in response to the COVID-19 pandemic"}],"relHost":[{"pubHistory":["14.1992 -"],"id":{"eki":["320418308"],"issn":["1537-6591"],"zdb":["2002229-3"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title_sort":"Clinical infectious diseases","title":"Clinical infectious diseases","subtitle":"electronic edition"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"extent":"8","pages":"S1-S8","year":"2025","text":"80(2025), Supplement_1, S1-S8","volume":"80"},"language":["eng"],"note":["Gesehen am 31.07.2023"],"recId":"320418308","origin":[{"dateIssuedDisp":"1992-","publisher":"Oxford Journals ; Univ. of Chicago Press, Journals Division","dateIssuedKey":"1992","publisherPlace":"Oxford ; Chicago, Ill."}],"disp":"Enhancing clinical trial sites in low- and middle-income countries to facilitate product development in response to the COVID-19 pandemicClinical infectious diseases"}],"physDesc":[{"extent":"8 S."}],"person":[{"given":"Sophie","role":"aut","display":"Kang, Sophie","family":"Kang"},{"role":"aut","given":"Birkneh Tilahun","family":"Tadesse","display":"Tadesse, Birkneh Tilahun"},{"given":"Hyon Jin","role":"aut","display":"Jeon, Hyon Jin","family":"Jeon"},{"given":"Mosoka P","role":"aut","display":"Fallah, Mosoka P","family":"Fallah"},{"display":"Dereje, Nebiyu","family":"Dereje","given":"Nebiyu","role":"aut"},{"display":"Ilesanmi, Olayinka Stephen","family":"Ilesanmi","given":"Olayinka Stephen","role":"aut"},{"display":"Abay, Solomon Mequanente","family":"Abay","given":"Solomon Mequanente","role":"aut"},{"family":"Tekle","display":"Tekle, Betelhem I","role":"aut","given":"Betelhem I"},{"given":"Hayoung G","role":"aut","display":"Son, Hayoung G","family":"Son"},{"display":"Shrestha, Laxman","family":"Shrestha","given":"Laxman","role":"aut"},{"given":"Anita","role":"aut","display":"Shrestha, Anita","family":"Shrestha"},{"family":"Ramiso","display":"Ramiso, Hasia V","role":"aut","given":"Hasia V"},{"role":"aut","given":"Vincent","family":"Canouet","display":"Canouet, Vincent"},{"display":"Kim, Yeonseon","family":"Kim","given":"Yeonseon","role":"aut"},{"display":"Asante, Kwaku Poku","family":"Asante","given":"Kwaku Poku","role":"aut"},{"role":"aut","given":"Japhet","family":"Anim","display":"Anim, Japhet"},{"family":"Kaali","display":"Kaali, Seyram","role":"aut","given":"Seyram"},{"given":"Maria Rosario","role":"aut","display":"Capeding, Maria Rosario","family":"Capeding"},{"given":"Ilesh V","role":"aut","display":"Jani, Ilesh V","family":"Jani"},{"family":"Capitine","display":"Capitine, Igor","role":"aut","given":"Igor"},{"display":"Mahumane, Arlete","family":"Mahumane","given":"Arlete","role":"aut"},{"family":"Wartel","display":"Wartel, T Anh","role":"aut","given":"T Anh"},{"display":"Haselbeck, Andrea Haekyung","family":"Haselbeck","given":"Andrea Haekyung","role":"aut"},{"family":"Saluja","display":"Saluja, Tarun","role":"aut","given":"Tarun"},{"role":"aut","given":"Florian","family":"Marks","display":"Marks, Florian"}]} | ||
| SRT | |a KANGSOPHIEENHANCINGC1520 | ||